Table 1.
ORF | Primer | Enzyme | Vector | KmR cassette | Insertion site |
---|---|---|---|---|---|
slr0114 | 5′; 5′-CTAAGCGGTACCGAATGTCC-3′ | KpnI | pBlueIIKS | KIND | NheI |
3′; 5′-GCTAACATGAGCTCCACGTC-3′ | SacI | ||||
slr1983 | 5′; 5′-CATCTAGCCCGGGCATATCA-3′ | XmaI | pBlueIIKS | KAPA | EcoRI |
3′; 5′-CCAAGAAAATGGTACCAC-3′ | KpnI | ||||
sll0602 | 5′; 5′-GGCCATGGTACCGCTTTTATCG-3′ | KpnI | pBlueIIKS | KAPA | ApaI |
3′; 3′-GCTAGCGGAGCTCTCATCTAAAC-3′ | SacI | ||||
sll1033 | 5′; 5′-GGGGATGGTGTTCTAGAATTAGCG-3′ | XbaI | pUC19 | KISS | KpnI |
3′; 5′-CCTACCGAGCTCGTGGAAACAG-3′ | SacI | ||||
sll1365 | 5′; 5′-GCTGGTACCATTGATTTTGCCC-3′ | KpnI | pBlueIIKS | KIXX | SmaI |
3′; 5′-CCTAGAGCTCTACGGCAGTG-3′ | SacI | ||||
sll1771 | 5′; 5′-CGATCAAGCTTTTCCGTTTCC-3′ | HindIII | pUC19 | KISS | KpnI |
3′; 5′-TTACCACTGGCGGAGCTCTCAT-3′ | SacI | ||||
sll1387 | 5′; 5′-GCCTACTGGCACCACCAAAA-3′ | HincII | pBlueIIKS | KIXX | BamHI |
3′; 5′-GGTCGAAACTTCCGCAAGCT-3′ | HindIII | ||||
sll1329 | 5′; 5′-GCCATTCCCAAGGGAGAAAAAG-3′ | XmaI | pUC19 | KIXX | (SfiI) blunt/SmaI |
3′; 5′-GCACGTAGAGCAAACTGAATTC-3′ | SalI | ||||
sll1770 | 5′; 5′-CCGGTACCGTGTTCACAGCGGGCATTATG-3′ | KpnI | pBlueIIKS | KIXX | SmaI |
3′; 5′-GCTCTAGACGTCCCTCTGGATCAAGGTA-3′ | XbaI |
The primers used to PCR amplify the corresponding open reading frames contained unique restriction sites, indicated in bold-face letters, for cloning the fragments into pBluescript II KS (Stratagene) or pUC 19 (Amersham Pharmacia) as indicated. The open reading frames of the resulting constructs were disrupted by inserting into unique restriction sites a kanamycine resistance (KmR) cartridge derived from either of the pUC4-KIND, pUC4-KAPA, pUC4-KISS or pUC4-KIXX plasmids (Amersham Pharmacia) as indicated.